Case 1:14-cv-01171-GMS Document 284 Filed 12/08/16 Page 1 of 287 PageID #: 7958 480

1 IN THE UNITED STATES DISTRICT COURT 2 IN AND FOR THE DISTRICT OF DELAWARE 3 4 IN RE COPAXONE 40 MG C.A. No. 14-1171-GMS ) CONSOLIDATED CASES ) (CONSOLIDATED) 5 6 Wilmington, Delaware. 7 Wednesday, September 28, 2016 9:00 a.m. 8 Day 3 of Bench Trial 9 -10 BEFORE: HONORABLE GREGORY M. SLEET, U.S.D.C.J. 11 **APPEARANCES:** 12 JOHN W. SHAW, ESQ., and KAREN E. KELLER, ESQ. 13 Shaw Keller LLP -and-14 PAUL W. WARE, ESQ., DARYL WIESEN, ESQ., 15 JOHN T. BENNETT, ESQ., ELIZABETH J. HOLLAND, ESQ., 16 NICHOLAS K. MITROKOSTAS, ESQ., and WILLIAM JAMES, ESQ., 17 Goodwin Procter LLP (Washington, D.C.) 18 -and-STEPHEN B. BRAUERMAN, ESQ., and 19 SARA BRUSSIERE, ESQ. Bayard P.A. 20 Counsel for Plaintiffs 21 22 23 24 25 DOCKE.

A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

```
1
      APPEARANCES CONTINUED:
 2
               FREDERICK L. COTTRELL, III, ESQ.
               Richards, Layton & Finger, P.A.
 3
                        -and-
               DAVID L. ANSTAETT, ESQ.
 4
               Perkins Coie LLP
                (Madison, WI)
 5
                        -and-
               SHANNON M. BLOODWORTH, ESQ.,
 б
               BRANDON M. WHITE, ESQ.
               EMILY J. GREB, ESQ., and
 7
               ROBERT D. SWANSON, ESQ.
               Perkins Coie, LLP
 8
                (Washington, D.C.)
 9
                                  Counsel for Defendants
                                  Mylan, Inc. and
10
                                  Mylan Pharmaceuticals, Inc.
11
               DOMINICK T. GATTUSO, ESQ.
               Procter Heyman & Enerio LLP
12
                        -and-
               WILLIAM A. RAKOCZY, ESQ.,
13
               DEANNE M. MAZZOCHI, ESQ.,
               RACHEL PERNIC WALDRON, ESQ.,
14
               MATTHEW V. ANDERSON, ESQ.,
               THOMAS H. ERLICH, ESQ.
15
               ERIN FORBES, ESQ., and
               CHRIS GALLIGAN, ESQ.
16
               Rakoczy Molino Mazzochi & Siwik LLP
               (Chicago, IL)
17
                                  Counsel for Defendants
18
                                   Sandoz Inc. and Momenta
                                  Pharmaceuticals, Inc.
19
               RICHARD W. RILEY, ESQ.
20
               Duane Morris LLP
                        -and-
21
               CHRISTOPHER S. KROON, ESQ., and
               ANTHONY J. FITZPATRICK, ESQ.
22
               Duane Morris LLP
               (Boston, MA)
23
                                  Counsel for Defendants
24
                                  Amneal Pharmaceuticals LLC
                                   and Amneal Pharmaceuticals
25
                                   Company GmbH
```

A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

DOCKET

Case 1:14-cv-01171-GMS Document 284 Filed 12/08/16 Page 3 of 287 PageID #: 7960 482 1 APPEARANCES CONTINUED: 2 DAVID BILSON, ESQ. Phillips, Goldman, McLaughlin & Hall, P.A. 3 -and-HANK HECKEL, ESQ. 4 Budd Larner (Short Hills, NJ) 5 Counsel for Defendant DRL 6 NEAL C. BELGAM, ESQ. 7 Smith Katzenstein & Jenkins LLP -and-8 E. ANTHONY FIGG, ESQ., ELIZABETH R. BRENNER-LEIFER, ESQ., and 9 BRETT A. POSTAL, ESQ. Rothwell, Figg, Ernst & Manbeck, P.C. 10 (Washington, D.C.) 11 Counsel for Defendants Synthon Pharmaceuticals, Inc., 12 Synthon B.V., and Synthon s.r.o., and Pfizer 13 14 15 16 17 18 19 20 21 22 23 24 25 DOCKET

A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

Case 1:14-cv-01171-GMS Document 284 Filed 12/08/16 Page 4 of 287 PageID #: 7961 483

1 THE COURT: Good morning. 2 (Counsel respond "Good morning.") 3 THE COURT: Please, take your seats. 4 I understand that we have an issue or two. Who 5 wants to go first? MR. WARE: Yes, Your Honor. I would appreciate 6 7 if the Court would entertain us at sidebar. 8 (The following took place at sidebar.) 9 MR. WARE: Your Honor, yesterday, we had some 10 colloquy about Mr. Hassler and the extent to which I would 11 be precluded from asking questions on irreparable harm. 12 THE COURT: Yes. 13 MR. WARE: I believe representations were 14 made -- I am not going to characterize those -- I asked for 15 the Bench conference in part because I don't want to 16 embarrass anybody -- but the representations were made to 17 you, including these: that he was never identified in 18 response to discovery requests; he was never identified as 19 someone who was going to have knowledge on irreparable harm 20 issues. 21 That is not true. Among other things, we gave in discovery his declaration filed in the U.S. Supreme 22 23 Court, the subject of which is irreparable harm. 24 In fairness, it has to do more with 20 milligram 25 than 40 milligram because that was the nature of the case.

**A R M** Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

DOCKF

Case 1:14-cv-01171-GMS Document 284 Filed 12/08/16 Page 5 of 287 PageID #: 7962 484

1 But the entire content is on the issue of irreparable harm. Defendants have marked that as a defense exhibit 2 3 in this case. He was deposed six months, ago and he was asked 4 5 time and time again about this issue in the deposition in this case. б 7 My feeling was that yesterday, knowing the premium the Court puts on fairness, that the Court felt that 8 9 defendants had not been given appropriate notice or an 10 opportunity. And that is absolutely not the case. He was 11 deposed endlessly on this. 12 That is my issue, Your Honor. We should be free 13 to inquire on this. I have a suggestion if we get to it. 14 MS. BLOODWORTH: Your Honor, if I may. First of all, this is the first we are hearing 15 about this. We met and conferred with plaintiffs many times 16 17 last night on a variety of issues and this was never brought 18 to our attention, that they were going to make this motion this morning. So I have no information in front of me about 19 20 what testimony Mr. Ware is actually referencing. 21 I can tell you that I was counsel for Mylan in the 20 milligram case which went to the Supreme Court. Mr. 22 23 Hassler submitted that harm declaration on whether or not

generic competition entry of the 20 milligram product 25 against Teva's 20 milligram product would cause irreparable

24

**A R M** Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

## DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

#### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.